Evaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy
Authors:
- Jing LiJLJing Li
- Peiyu LiPLPeiyu Li
- Tereza BrachtlovaTBTereza Brachtlova
- Ida H. van der Meulen-MuilemanIMIda H. van der Meulen-Muileman
- Henk DekkerHDHenk Dekker
- Vishal S. KumarVKVishal S. Kumar
- Marieke FransenMFMarieke Fransen
- Idris BahceIBIdris Bahce
- Emanuela Felley-BoscoEmanuela Felley-Bosco
- Victor W. van BeusechemVBVictor W. van Beusechem
Open Access
- 6 December 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 13131
Abstract
The core spliceosome Sm proteins are gaining attention as potential targets for cancer treatment. Here, we evaluate this, with focus on SmD2. A pan-cancer analysis including 26 solid tumor types revealed that the SmD2-encoding SNRPD2 gene was overexpressed in almost all cancers. In several cancers, high SNRPD2 expression was associated with a poor prognosis. To investigate the vulnerability of human cells to the loss of SmD2 expression, we silenced SNRPD2 using a short hairpin-expressing lentiviral vector in established cancer cell lines; in short-term cultured melanoma cells; and in several normal cell cultures, including cancer-associated fibroblasts cultured from non-small cell lung cancer resections. Additionally, we analyzed publicly available cell viability datasets for the dependency of cancer cell lines to SmD2 expression. Together, these studies clearly established SmD2 as a cancer-selective lethal target. Delving into genes with similar essentiality profiles to SNRPD2, we uncovered the intersected lethal stress between the loss of SmD2 and the loss of gene products participating in not only different mRNA processing steps including mRNA splicing, but also processes for coordinated protein production, as well as mitosis. Furthermore, we could correlate SNRPD2 expression to the responses of cancer cells to several FDA-approved anti-tumor drugs, especially to drugs inhibiting the cell cycle. Overall, our study confirms the anticipated role for targeting SmD2 in cancer treatment and reveals non-canonical SmD2 functions beyond mRNA splicing that could contribute to the dependency of cancer cells to high SNRPD2 expression.Keywords
Funding Information
- Walter Brückerhoff Stiftung (201807040045, 202208140002)
- China Scholarship Council (201807040045, 202208140002)
This publication has 42 references indexed in Scilit:
- SNRPD1 inhibition suppresses the proliferation of hepatocellular carcinoma and promotes autophagy through the PI3K/AKT/mTOR/4EBP1 pathwayArchives of Biochemistry and Biophysics, 2023
- A unified platform enabling biomarker ranking and validation for 1562 drugs using transcriptomic data of 1250 cancer cell linesComputational and Structural Biotechnology Journal, 2022
- Emerging roles of spliceosome in cancer and immunityProtein & Cell, 2021
- Discrimination and Calibration of Clinical Prediction ModelsJAMA, 2017
- Defining a Cancer Dependency MapCell, 2017
- A Landscape of Pharmacogenomic Interactions in CancerCell, 2016
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- Technologies for deriving primary tumor cells for use in personalized cancer therapyTrends in Biotechnology, 2013
- Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccinesCancer Immunology, Immunotherapy, 2008
- Melanoma-associated antigen recognized by T cells (MART-1)Cancer, 1999